Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8WVQ1

UPID:
CANT1_HUMAN

ALTERNATIVE NAMES:
Apyrase homolog; Putative MAPK-activating protein PM09; Putative NF-kappa-B-activating protein 107

ALTERNATIVE UPACC:
Q8WVQ1; B4DJ54; Q7Z2J7; Q8NG05; Q8NHP0; Q9BSD5

BACKGROUND:
The enzyme Soluble calcium-activated nucleotidase 1, recognized by its alternative names Apyrase homolog, Putative MAPK-activating protein PM09, and Putative NF-kappa-B-activating protein 107, prioritizes UDP in its calcium-dependent nucleotidase activity. Its significant function in proteoglycan synthesis suggests its importance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Given its association with conditions like Desbuquois dysplasia 1 and multiple Epiphyseal dysplasia, 7, the enzyme's therapeutic potential is evident. The exploration of Soluble calcium-activated nucleotidase 1's function could lead to novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.